Abstract
Tumor immunotherapy is currently a hot research topic in the field of oncology, and is an efficacious mode of tumor treatment. Programmed cell death receptor PD-1 (PD-1) is an important immunosuppressive molecule, which is mainly expressed in activated T and B cells. PD-1/PD-L1 inhibitors can block the binding of PD-1 to PD-L1, block the negative regulatory signals, and restore the activity of T cells, thus enhancing the immune response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
